IMAC Holdings, Inc. Announces Initiation of Third and Final Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for…

BRENTWOOD, Tenn, March 24, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc.(Nasdaq:IMAC) (IMAC or the Company), today announces it has initiated the third and final cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinsons disease.

About IMACs Phase 1 Clinical Trial

The Phase 1 clinical trial, consisting of a 15-patient dose escalation safety and tolerability study, is being conducted at IMAC Regeneration Centers inChesterfield, Missouri,Paducah, Kentucky, andBrentwood, Tennessee. The trial is divided into three groups: 1) five patients with bradykinesia due to Parkinsons disease received a low dose, intravenous infusion of stem cells which was completed February 26, 2021, 2) five patients received a medium dose intravenous infusion which was completed February 16, 2022, 3) and five patients will receive a high concentration dose intravenous infusion. IMACs medical doctors and physical therapists at the clinical sites have been trained to administer the treatment and manage the therapy.Ricardo Knight, M.D., M.B.A., who is medical director of the Mike Ditka IMAC Regeneration Center, is the trials principal investigator.

About Bradykinesia Due to Parkinsons Disease

In addition to unusually slow movements and reflexes, bradykinesia may lead to limited ability to lift arms and legs, reduced facial expressions, rigid muscle tone, a shuffling walk, and difficulty with repetitive motion tasks, self-care, and daily activities. Parkinsons disease is the typical culprit of bradykinesia, and as it progresses through its stages, a persons ability to move and respond declines.

According toZion Market Research, the global Parkinsons disease therapeutics market was$2.61 billionin 2018 and is expected to grow to$5.28 billionby 2025. The ParkinsonsDisease Foundationestimates that nearly 10 million people are suffering from Parkinsons disease, and almost 60,000 new cases are reported annually in theU.S.

AboutIMAC Holdings, Inc.

IMACwas created inMarch 2015to expand on the footprint of the original IMAC Regeneration Center, which opened inKentuckyinAugust 2000. IMAC Regeneration Centers combine life science advancements with traditional medical care for movement restricting diseases and conditions.IMACowns or manages over 15 outpatient medical clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. It has partnered with several active and former professional athletes including Ozzie Smith, David Price, Mike Ditka and Tony Delk to emphasize its focus treating sports and orthopedic injuries and movement-restricting diseases without surgery or opioids. IMAC also operates the BackSpace retail spine health and wellness treatment centers. More information aboutIMAC Holdings, Inc.is available atwww.imacholdings.com.

# # #

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as anticipate, expect, believe, may, will, should or other comparable terms, are based largely onIMAC'sexpectations and are subject to a number of risks and uncertainties, certain of which are beyondIMAC'scontrol. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to retain personnel who possess the skills and experience necessary to meet trial requirements and its ability to protect its intellectual property.IMACencourages you to review other factors that may affect its future results in its registration statement and in its other filings with theSecurities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact:

Laura Fristoe

lfristoe@imacrc.com

Continued here:
IMAC Holdings, Inc. Announces Initiation of Third and Final Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for...